Rising Prostate Cancer Cases Fueling The Growth Of The Market Due To Increasing Aging Population Is Supporting Development Across The Androgen Deprivation Therapy Market

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

What Market Size Is Forecasted For The Androgen Deprivation Therapy Market By 2030 Based On Its 2026 Value?

The androgen deprivation therapy market has experienced substantial growth in recent years. Projections indicate it will expand from $8.31 billion in 2025 to $8.83 billion in 2026, achieving a compound annual growth rate (CAGR) of 6.3%. Historically, this growth can be attributed to factors such as limited treatment options for prostate cancer, a reliance on conventional surgery, the slow adoption of injectable therapies, low patient awareness of androgen deprivation therapy, and restricted availability of advanced therapies.

The androgen deprivation therapy market is anticipated to experience robust growth over the next few years, with its size projected to reach **$11.1 billion in 2030, driven by a compound annual growth rate (CAGR) of 5.9%.** This expansion during the forecast period is primarily attributed to the development of innovative anti-androgen drugs, increasing investment in gene and immunotherapies, a growing geriatric male population, the proliferation of specialty clinics and hospital oncology departments, and the integration of digital monitoring and telehealth solutions. Significant trends expected in this period include the rising adoption of LHRH agonists and antagonists, the expanded use of combination and targeted therapies, the growth in minimally invasive surgical procedures, an increased focus on patient-specific and age-based treatments, and enhanced monitoring and follow-up care for prostate cancer patients.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25692&type=smp

Which Drivers Are Advancing The Androgen Deprivation Therapy Market Growth?

The rising occurrence of prostate cancer is projected to stimulate expansion within the androgen deprivation therapy market over the next few years. This malignancy develops in the prostate gland, an organ in the male reproductive system that produces seminal fluid. Its frequency is escalating largely because people are living longer, with advanced age notably increasing the likelihood of developing this condition. Androgen deprivation therapy (ADT) serves as a principal treatment approach for prostate cancer, focusing on reducing androgen levels which promote tumor growth. It is commonly employed in advanced or metastatic phases to slow the disease’s advancement. For example, a report released by Prostate Cancer UK, a UK-based organization dedicated to prostate cancer research, awareness, and support, revealed in January 2025 that in England, prostate cancer diagnoses rose from 50,751 cases in 2022 to 55,033 cases in 2023, demonstrating a distinct year-on-year increase in incidence. Consequently, the growing incidence of prostate cancer is propelling the expansion of the androgen deprivation therapy market.

Which Segment-Based Categories Are Covered In The Androgen Deprivation Therapy Market?

The androgen deprivation therapy market covered in this report is segmented –

1) By Type: Medicine, Surgery, Other Types

2) By Route Of Administration: Injectable, Oral

3) By Patient Demographics: Men Aged 40-60, Men Aged 61-75, Men Above 75

4) By Application: Prostate Cancer, Other Applications

5) By End-User: Hospitals, Specialty Clinics, Other End-Users

Subsegments:

1) By Medicine: LHRH Agonists, LHRH Antagonists, Anti-Androgens, CYP17 Inhibitors, Steroidal Anti-Androgens, Non-Steroidal Anti-Androgens, Estrogen-Based Therapies, Combination Therapies

2) By Surgery: Bilateral Orchiectomy, Subcapsular Orchiectomy, Simple Orchiectomy

3) By Other Types: Radiopharmaceutical Therapy, Gene Therapy, Immunotherapy, Targeted Therapy, Cryotherapy, High-Intensity Focused Ultrasound (HIFU

Which Trends Are Contributing To Changes In The Androgen Deprivation Therapy Market?

Major companies operating within the androgen deprivation therapy (ADT) market are concentrating on developing advanced solutions, including oral androgen receptor inhibitors (ARIs), to provide more convenient, tolerable, and effective treatment options for individuals with prostate cancer. These oral ARIs represent targeted therapies that directly block androgen receptor activity in prostate cancer cells, thereby preventing tumor growth without requiring frequent clinic-administered hormone-suppressing injections. For instance, in June 2025, Bayer AG, a Germany-based multinational pharmaceutical company, obtained US Food and Drug Administration (FDA) approval for Nubeqa (darolutamide), an oral ARI intended for use in combination with ADT to treat metastatic hormone-sensitive prostate cancer (mHSPC). Engineered to improve clinical outcomes and patient quality of life, Nubeqa inhibits androgen receptor signaling with high binding affinity, demonstrates minimal blood–brain barrier penetration to limit central nervous system side effects, and showed a 46% reduction in the risk of radiological progression or death when compared to placebo plus ADT, as observed in the Phase III ARANOTE trial.

Which Key Players Are Active In The Androgen Deprivation Therapy Market?

Major companies operating in the androgen deprivation therapy market are Johnson & Johnson Services Inc., Astellas Pharma Inc., Ipsen S.A., Ferring Pharmaceuticals SA, Tolmar Pharmaceuticals Inc., Pfizer Inc., Novartis AG, Dr. Reddy’s Laboratories Ltd., Orion Corporation, Besins Healthcare S.A., Veru Inc., Kintor Pharmaceutical Limited, Foresee Pharmaceuticals Co. Ltd., Lawley Pharmaceuticals Pty Ltd., AbbVie Inc., Sanofi S.A., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Hikma Pharmaceuticals PLC, Lupin Limited, Cipla Ltd., Accord Healthcare Ltd., Mylan N.V. (Viatris), Zydus Lifesciences Ltd., Apotex Inc., Amneal Pharmaceuticals LLC, Glenmark Pharmaceuticals Ltd., Alembic Pharmaceuticals Ltd., Intas Pharmaceuticals Ltd., Torrent Pharmaceuticals Ltd., Aurobindo Pharma Ltd., Alvogen Inc., BCN Peptides SA, Chugai Pharmaceutical Co. Ltd., Sumitomo Pharma Co. Ltd.

Access The Complete Androgen Deprivation Therapy Market Report:

https://www.thebusinessresearchcompany.com/report/androgen-deprivation-therapy-global-market-report

Which Region Holds The Largest Share In The Androgen Deprivation Therapy Market?

North America was the largest region in the androgen deprivation therapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the androgen deprivation therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Androgen Deprivation Therapy Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=25692&type=smp

Browse Through More Reports Similar to the Global Androgen Deprivation Therapy Market 2026, By The Business Research Company

Hormone Therapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/hormone-therapy-global-market-report

Testosterone Replacement Therapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/testosterone-replacement-therapy-global-market-report

Drugs For Hormonal Replacement Therapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/drugs-for-hormonal-replacement-therapy-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795